Expression of Nrf2 in neurodegenerative diseases - Wikidata - awgldk - TriplyDB

Expression of Nrf2 in neurodegenerative diseases

Expression of Nrf2 in neurodegenerative diseases

http://www.wikidata.org/entity/Q36477584

about

Nuclear transport, oxidative stress, and neurodegeneration Nuclear factor erythroid 2-related factor 2 facilitates neuronal glutathione synthesis by upregulating neuronal excitatory amino acid transporter 3 expression.Cellular interplay between neurons and glia: toward a comprehensive mechanism for excitotoxic neuronal loss in neurodegeneration microRNAs: Emerging Targets Regulating Oxidative Stress in the Models of Parkinson's Disease Redox Imbalance and Viral Infections in Neurodegenerative Diseases Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels Mitochondrial Dysfunction Contributes to the Pathogenesis of Alzheimer's Disease The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases The role of free radicals in the aging brain and Parkinson's Disease: convergence and parallelism Oxidative stress responses and NRF2 in human leukaemia Mitochondrial quality control: decommissioning power plants in neurodegenerative diseases Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin Binding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complex Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases Dual TNFα-induced effects on NRF2 mediated antioxidant defence in astrocyte-rich cultures: role of protein kinase activation Activated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and GSK3β Stress-activated cap'n'collar transcription factors in aging and human disease CACUL1/CAC1 Regulates the Antioxidant Response by Stabilizing Nrf2 Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters Time-dependent effects of systemic lipopolysaccharide injection on regulators of antioxidant defence Nrf2 and PGC-1α in the neonatal rat brain Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection NRF2-regulation in brain health and disease: implication of cerebral inflammation Salvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease models The status of Nrf2-based therapeutics: current perspectives and future prospects Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases Altered transcription factor trafficking in oxidatively-stressed neuronal cells.Antroquinonol Lowers Brain Amyloid-β Levels and Improves Spatial Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease.Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease.Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease.Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease.The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases.Genetic Variations and mRNA Expression of NRF2 in Parkinson's Disease.Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity.Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription.NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's disease Hydrogen peroxide responsive miR153 targets Nrf2/ARE cytoprotection in paraquat induced dopaminergic neurotoxicity.Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease

P2860

Q24624357-019E8F1D-5D78-4DBD-8BD2-138B87845E7E Q24631707-C9BF001E-EBBD-4D78-9A96-84AAD8427A8D Q24654460-2C21E302-64A5-481F-8C52-9A04852191D8 Q26738440-4616EA2D-BCBB-4A1F-B29C-82E80F5609E1 Q26750630-3EDBF6B5-71E8-4069-B3B7-99E775BCF784 Q26751266-7FC8CB34-7BDB-42D9-AC3F-1E2CE5ADDA69 Q26751302-400DF395-87C1-40B7-9129-495D05B14AB7 Q26801929-0960121B-5F1A-4BC9-AC70-C999C77EECD7 Q26822972-87FD2D79-AADF-41D9-BF0B-BEA8ACB2B456 Q26852148-913CA1D6-1ABB-4386-B64B-63A9DBFF4903 Q26864239-A65D9640-6F06-4567-BA53-75F55787C7F3 Q27009213-1D70078B-000F-4448-AEEE-8B633632C29C Q27312215-D082AD2D-0B05-4F2E-A960-FA1CCBB4B88D Q27689053-10ADCAA7-49DE-4627-BDC7-A2A478C9FDFF Q28259010-FA57F3AF-2D02-4087-908B-0E10602AB39F Q28383476-DD0A6ADB-BF1B-46AF-B526-77C5B1E5510D Q28383951-41AF11ED-942C-4D79-8D8B-929B00561530 Q28384783-99D72CCA-50C5-42CD-A07A-A8908F7965E0 Q28384997-07EA33DD-5ED7-4941-87AB-3EAE34DF34DB Q28386244-02929A5D-459F-4FF8-929F-3FFF2662AA99 Q28389828-E1931700-0D7D-4258-AF9B-6B1F24430AE1 Q28390052-D9EEEA06-1799-4742-9CB8-142C0B441DCF Q28396785-DCD112A0-5817-4AD9-8188-D7AC83328243 Q28397785-7AA48157-DB7D-411B-817E-82D4CE7FB0AF Q28540349-45D2C0E8-F528-4DD8-825A-05BBA4ECA557 Q28818264-0EC95709-C86F-455A-ABF7-C3097660D959 Q28818353-E73008AC-9872-43CC-8275-CE46F03B6D86 Q29247921-77BAB43D-8FD2-4152-AEEC-64A299285EC8 Q30419484-27EB76FB-12D9-4E46-A86D-C1D1CB1FD6AE Q30668645-2602076A-2957-4343-A43C-2735872E1506 Q30847085-27B5821B-A96E-40B7-9982-2A1D4AF768E1 Q33536124-D60AC1B5-FBD0-4356-85D3-ED866778AD10 Q33614523-C5C687EC-46B2-4600-891B-4182A2C2589C Q33659621-065958E6-101D-4A86-BF1D-00FAF82F7E07 Q33692840-199CB745-C859-4CCF-8ACA-10A8676E64A6 Q33800053-C70FE194-B4F5-43E1-B6A2-73C9EA038088 Q33912442-AEC9C536-355C-41CF-A920-1401071C01BA Q33958143-FB88664A-5F9D-4567-9939-91D31E8BC490 Q34004577-7D1CFA37-8E7B-4585-8A1D-FB8624DD4C08 Q34043950-1CC4C2B2-D94C-4051-ACBB-0033E278FBC3

P2860

Expression of Nrf2 in neurodegenerative diseases

http://www.wikidata.org/entity/Q36477584

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Expression of Nrf2 in neurodegenerative diseases

@ast

Expression of Nrf2 in neurodegenerative diseases

@en

type

label

Expression of Nrf2 in neurodegenerative diseases

@ast

Expression of Nrf2 in neurodegenerative diseases

@en

prefLabel

Expression of Nrf2 in neurodegenerative diseases

@ast

Expression of Nrf2 in neurodegenerative diseases

@en

P1433

Q36477584-49022352-2555-4319-8109-E7133DB67EA3

P1476

Q36477584-D0BFB688-EE35-4FDA-947B-3AF4C11A320E

P2093

Q36477584-3A377E6D-6102-475F-A7A0-413B014A8ED3

Q36477584-7B455D73-4D2E-443C-97B7-9C37A1C17808

Q36477584-7FAFF953-45D1-4BBB-9362-E633A489B497

Q36477584-C68BBBAB-239F-453B-863F-B6D471E7756D

Q36477584-CCFFDAC8-2182-4A0C-BC98-E7CBA2705026

Q36477584-D625BD95-EA03-4D6A-B6C5-DE8C58A3B06C

Q36477584-E3B196E5-1303-4584-B7F3-498FCE3F8F47

Q36477584-FEE251F7-F7D1-494E-BC02-12D3458842A0

Q36477584-FF466820-E482-47BF-B891-1D6483180A7D

P2860

Q36477584-03B39AB9-40F3-4534-98D1-25F24CBB6122

Q36477584-05057AAF-5784-4ACE-BD23-30A30676AABA

Q36477584-06BF8975-781A-4912-B2B3-7A7169586723

Q36477584-10A9A44B-9BEB-4D4F-BE12-A064B19D661B

Q36477584-11657522-0904-4F6D-9A87-1A11548D89AA

Q36477584-126C4BFC-F936-4850-8B90-A9473131FF9E

Q36477584-206F9CBF-847F-40CE-B0FB-05E8E2313BCE

Q36477584-262C0E5A-788F-4489-A08D-6633B3E5C022

Q36477584-2ACD7746-CF84-4213-AE27-2F4DD155AB95

Q36477584-2CAC44FC-A865-4D33-B658-5DF59FA3A37B

P304

Q36477584-14F16BEC-7C0F-4790-8295-2CE0E4DE1D2F

P31

Q36477584-F205F64F-4D2E-4D3A-B61A-12A5070BE773

P356

Q36477584-00D624F9-49ED-4723-861A-9EEDCCEC8C2A

P433

Q36477584-A33B1803-47C6-41ED-861C-9223FADA0883

P478

Q36477584-6D672862-DA0F-4162-ADFD-10F52C0F88D6

P577

Q36477584-A6E57D06-B914-4694-94B1-15396155D5D2

P5875

Q36477584-25DEF0FB-8856-45F1-A06F-AD26762FFA74

P698

Q36477584-8A38A0B8-3ED3-4D44-A3CF-A3DCFB2BF62B

P921

Q36477584-989469B6-CD90-4911-AA18-441AF7CD8876

P932

Q36477584-4559AF48-7CE5-4188-A78B-529E8B4B5C01

P356

NEN.0B013E31802D6DA9

P1433

Journal of Neuropathology & Experimental Neurology

P1476

Expression of Nrf2 in neurodegenerative diseases

@en

P2093

Charleen T Chu

http://www.w3.org/2001/XMLSchema#string

Charles A Glass

http://www.w3.org/2001/XMLSchema#string

Chenere P Ramsey

http://www.w3.org/2001/XMLSchema#string

Gillian P Ritson

http://www.w3.org/2001/XMLSchema#string

Kathryn A Lindl

http://www.w3.org/2001/XMLSchema#string

Kelly L Jordan-Sciutto

http://www.w3.org/2001/XMLSchema#string

Luis A Chia

http://www.w3.org/2001/XMLSchema#string

Marshall B Montgomery

http://www.w3.org/2001/XMLSchema#string

Ronald L Hamilton

http://www.w3.org/2001/XMLSchema#string

P2860

Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain

Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival

Neuropathological stageing of Alzheimer-related changes

Staging of brain pathology related to sporadic Parkinson's disease

Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response e

The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm

Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants

An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements

Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione

Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine

P304

75-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/NEN.0B013E31802D6DA9

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6596072

http://www.w3.org/2001/XMLSchema#string

P698

17204939

http://www.w3.org/2001/XMLSchema#string

P921

neurodegeneration

P932

2253896

http://www.w3.org/2001/XMLSchema#string